CERN scientists 'transport' antimatter from France to Switzerland
Scientists at CERN have successfully transported antimatter outside their laboratory for the first time, marking a breakthrough in physics research.
The European research centre developed a specialised two-metre-long containment device to safely carry antimatter over a four-kilometre (2.5-mile) journey.
The antimatter was transported by truck across the CERN campus, crossing the border from France into Switzerland before returning to its starting point.
The achievement, detailed in a paper published in the journal Nature, demonstrates the potential to move antimatter to laboratories across Europe via public roads.
'This experiment confirms the feasibility of relocating trapped protons without loss, operating autonomously without external power for four hours,' the study stated. 'It opens the way to transferring antimatter to low-noise research facilities in the vicinity and beyond.'
Antimatter, which is essential to understanding the universe and fundamental physics, is notoriously difficult to produce and contain.
CERN WANTS TO SHIP ANTIMATTER ACROSS EUROPE... IN A BOX?
Antimatter is real. It explodes if it touches anything.
So yeah, transporting it is tricky.
CERN—the same lab with the giant particle collider—just built a 2-meter-long container that keeps antimatter cold (5 Kelvin),… pic.twitter.com/K6jlG51tx7 — Mario Nawfal (@MarioNawfal) May 20, 2025
It requires particle collisions at near-light speeds and magnetic traps to prevent it from annihilating on contact with normal matter.
Only a handful of facilities worldwide can generate antimatter.
CERN's success in transporting antimatter safely could enable expanded research capabilities at institutions such as Heinrich Heine University Düsseldorf in Germany, located nearly 800 kilometres from CERN, which is expected to be among the first to receive antimatter shipments.
Researchers hailed the experiment as the beginning of a 'new era in precision antimatter research' that may unlock deeper insights into the nature of space and matter.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
6 days ago
- Express Tribune
Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio
In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion. The deal was announced by a press release on Sanofi's website. It is the largest by a European healthcare company this year and will see Sanofi paying $129 per share in cash, a significant premium that sent Blueprint's stock soaring in premarket trading. Blueprint Medicines, known for its specialty in treating systemic mastocytosis a rare blood disorder marked by the overproduction of mast cells brings to Sanofi a strong foothold in a niche yet critical area of medicine. The acquisition adds the FDA-approved drug Ayvakit, the only treatment for advanced systemic mastocytosis, to Sanofi's growing immunology portfolio. Sanofi CEO Paul Hudson framed the deal as a strategic leap forward, enhancing the company's pipeline and reinforcing its transformation into a global leader in immunology. We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases. — Sanofi (@sanofi) June 2, 2025 With a promising pipeline including next-generation therapies like elenestinib and BLU-808, the acquisition fits into Sanofi's broader ambition of innovation despite recent setbacks, including a failed lung disease drug trial. Industry analysts from JP Morgan praised the acquisition for its strategic and financial merits, forecasting Ayvakit could generate $2 billion in annual sales by 2030. Sanofi's ongoing spree of acquisitions, including Vigil Neuroscience and Inhibrx, signals a company doubling down on R&D investments to reshape its future. The acquisition aligns with Sanofi's broader strategy to invest heavily in US manufacturing and research, tapping into incentives and momentum driven by recent government policies. With Blueprint Medicines now joining its portfolio, Sanofi cements its stake in cutting-edge immunology treatments and rare disease therapies, positioning itself for long-term growth in a competitive pharmaceutical landscape.
Express Tribune
29-05-2025
- Express Tribune
Anti-aging drugs extend lifespan in mice, spark hope for human longevity Excerpt (117 characters):
In a quietly remarkable advance from European researchers, a pair of existing cancer drugs rapamycin and trametinib have been shown to extend the lifespans of mice by up to 35 percent. The study, conducted by scientists at the Max Planck Institute for Biology of Ageing in Germany, offers promising evidence that longevity-enhancing interventions might not only lengthen life but also delay the onset of age-related diseases. While rapamycin has long been studied for its life-extending potential in animals, trametinib was previously shown to increase the lifespan of fruit flies. The real revelation, however, came when the two drugs were combined. Mice given both compounds not only lived longer but also aged more gracefully exhibiting fewer tumours, reduced inflammation in multiple organs, and better heart and muscle health in old age. Female mice experienced median lifespan increases of nearly 35 percent, with males not far behind at 27.4 percent. Maximum lifespan gains were similarly impressive. Researchers attribute the effect to the drugs' distinct points of action within the Ras/Insulin/TOR pathway, which regulates growth and aging. Notably, no additional side effects were observed when the drugs were used together—an encouraging sign for future human applications. Linda Partridge, a geneticist and co-senior author of the study, noted that while humans shouldn't expect to add decades to their lifespans, the real value might lie in extending the period of life lived in good health. The study adds to a growing body of research suggesting that aging is not only modifiable but potentially treatable. With both drugs already approved for human use in the US and EU, clinical trials to test their anti-aging effects could begin soon.
Business Recorder
26-05-2025
- Business Recorder
Astronomers spot galaxy shaped like the Milky Way but is far more massive
WASHINGTON: Astronomers have observed a galaxy dating to an earlier epoch in the universe's history that surprisingly is shaped much like our Milky Way - a spiral structure with a straight bar of stars and gas running through its center - but far more massive, offering new insight into galactic formation. The distant galaxy, called J0107a, was observed as it appeared 11.1 billion years ago, when the universe was about a fifth of its current age. The researchers used data from the Chile-based Atacama Large Millimeter/submillimeter Array (ALMA) and NASA's James Webb Space Telescope to study the galaxy. They determined that the galaxy's mass, including its stars and gas, was more than 10 times greater than that of the Milky Way, and it was forming stars at an annual rate approximately 300 times greater. J0107a was more compact than the Milky Way, however. 'The galaxy is a monster galaxy with a high star formation rate and plenty of gas, much more than present-day galaxies,' said astronomer Shuo Huang of the National Astronomical Observatory of Japan, lead author of the study published this week in the journal Nature. 'This discovery,' said study co-author Toshiki Saito, an astronomer at Shizuoka University in Japan, 'raises the important question: How did such a massive galaxy form in such an early universe?' While a few galaxies that are undergoing star formation at a similar rate to J0107a exist in today's universe, almost all of them are ones that are in the process of a galactic merger or collision. There was no sign of such circumstances involving this galaxy. J0107a and the Milky Way have some commonalities. 'They are similarly huge and possess a similar barred structure. However, the Milky Way had plenty of time to form its huge structures, while J0107a didn't,' Saito said. In the first few billion years after the Big Bang event 13.8 billion years ago that initiated the universe, galaxies were turbulent entities and were much richer in gas than those existing currently - factors that fostered extreme bursts of star formation. While galaxies with highly organized structures like the barred spiral shape of the Milky Way are common now, that was not the case 11.1 billion years ago. 'Compared to other monster galaxies in the distant universe (dating to an earlier cosmic epoch) whose shapes are usually disturbed or irregular, it is unexpected that J0107a looks very similar to present-day spiral galaxies,' Huang said. 'Theories about the formation of present-day galactic structures may need to be revised,' Huang added. The Webb telescope, as it peers across vast distances back to the early universe, has found that galaxies with a spiral shape appeared much earlier than previously known. J0107a is now one of the earliest-known examples of a barred spiral galaxy. About two thirds of spiral galaxies observed in the universe today possess a bar structure. The bar is thought to serve as a form of stellar nursery, bringing gas inward from the galaxy's spiral arms. Some of the gas forms what are called molecular clouds. Gravity causes the contraction of these clouds, with small centers taking shape that heat up and become new stars. The bar that is part of J0107a measures about 50,000 light years in length, Huang said. A light-year is the distance light travels in a year, 5.9 trillion miles (9.5 trillion km). The Webb telescope 'has been studying the morphology of early massive galaxies intensely recently. However, their dynamics are still poorly understood,' Saito said.
